My understanding is that all research and development is expensed at T1, so it should not be held on balance sheet. The question would be whether the product will be released on time, as they haven’t released much on time recently. They still seem to make sales though.
$14.8 claim against T1, page-8
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TNE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$31.28 |
Change
0.390(1.26%) |
Mkt cap ! $7.662B | |||
| Open | High | Low | Value | Volume |
| $30.99 | $31.38 | $30.86 | $6.079M | 195.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 217 | $31.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $31.29 | 212 | 9 |
View Market Depth
| Last trade - 12.40pm 04/12/2024 (20 minute delay) ? |
| TNE (ASX) Chart |
